NINGXIA QIYUAN PHARMACEUTICAL CO.,LTD.
Ningxia Qiyuan Pharmaceutical Co., Ltd. (hereafter called Qiyuan Pharma.) was incorporated from former Ningxia Pharmaceutical Factory & Ningxia Chinese Traditional Medicine Factory since Jan. 2001. Through development of more than 20 years, the company has been a well-known modern large-scale comprehensive biopharmaceutical enterprise in China and abroad.
The company relies on suitable biopharmaceuticals environmental conditions in Ningxia’s regional, dedicated on development and production of antibiotic APIs, Vitamin APIs and deep processing of corn. In the field of Tetracycline and Erythromycin APIs, the company is one of the 3 world's three largest suppliers, the Vitamin C series products occupy a place in the domestic and international markets due to their scale and quality.
Qiyuan Pharmaceutical has been recognized as a high-tech enterprise, with an enterprise technology center and a postdoctoral research workstation. The company's Erythromycin and Tetracycline Hydrochloride APIs have got certifications from the US FDA, European COS, and EUGMP certification, and passed official quality audits in multiple countries, such as India, Japan etc. Vitamin C products have also passed international food certifications, such as HALAL, KOSHER etc. The company's products are widely sold to dozens of countries and regions, including Europe, South America, Africa, Southeast Asia etc. The registered trademark "Qiyuan" of the company has been recognized as a "Famous Trademark of Ningxia" by the Administration for Industry and Commerce of Ningxia Hui Autonomous Region for many times.
The company has been awarded multiple honorary titles, including "AAA Integrity Pharmaceutical Enterprise" and "A-Level Tax Credit Unit" in the autonomous region, and "Contract Abiding and Creditworthy Enterprise" in the country, autonomous region, and Yinchuan city.
NINGXIA QIYUAN CHINESE MEDICINE CO.,LTD.
Ningxia Qiyuan National Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Qiyuan Industrial Investment, which is a high-tech enterprise established in 2001. The company integrates scientific research, production and sale, and has been recognized as the "Enterprise Technology Center", "Technology Innovation Center for Traditional Chinese Patent Medicines of Ningxia" and "Specialized and Innovative Example Enterprise". The company has production capacity of Chinese and Western medicine preparations with five major dosage forms, including tablet, granule, capsule, pill, and suppository, health foods and traditional Chinese medicine extracts. The main products include Jinlian Qingre series, goji berry series, hawthorn essence lipid-lowering series, and Vitamin C series. The company adheres to enterprise purpose of "Building Reputation in World, Promoting Healthy China" and value concept of "Caring Employees, Advocating Creativity", and has been a key enterprise in the pharmaceutical industry in Ningxia.
NINGXIA QIYUAN MEDICINE CO.,LTD.
Ningxia Qiyuan Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Qiyuan Industrial Investment, which is established in 2002, focused on pharmaceutical distribution, wholesale, and retail chain businesses. The company mainly deals in traditional Chinese patent medicines and Chinese medicinal herbs, Chinese herbal decoction pieces, chemical APIs and their preparations, antibiotics and their preparations, biochemical drugs, biological products, Class II psychotropic drugs, anabolic agents and peptide hormones, medical devices etc. In Ningxia region, we own many directly operated chain pharmacies. The company has perfect quality management system, advanced facilities and equipment, the information management system is also equipped, which can achieve full process quality control of drug procurement, storage and sale etc.
NINGXIA YUYUAN BIOTECHNOLOGY CO.,LTD.
Ningxia Yuyuan Biotechnology Co., Ltd. is a wholly-owned subsidiary of Ningxia Qiyuan Pharmaceutical Co., Ltd., established in October 2014 with a registered capital of 20 million RMB. The company covers an area of 483333 m2 (approximately 725 acres), which the building area is 8000 m2. As a high-tech enterprise which is based on biochemical production, Yuyuan Biotechnology has mature technology on D-sorbitol production field and is the exclusive producer within autonomous region, which has obvious regional advantages and excellent product quality control.
The main products include D-sorbitol and hydrogen gas. The hydrogen gas is used for D-sorbitol production, and major industrial raw material, industrial gas and specialty gas.
Qiyuan Philosophy
Care Staff, Advocate Innovation
Business can Sustain, Employees can Achieve
R&D Center
R&D of Drug
Product in Hand, Quality in Mind
Care Health
Care for Health, Improve the Quality of Life
Create better products, Do a good job in health industry
Customer Service
Feedback Valuable Opinions
Sincere Service for You
Development History
History
1. In May 1967, the construction of Ningxia Pharmaceutical Factory started.
2. In February 1969, Xi'an Pharmaceutical Factory sent 40 key production technicians including Zhang Yushan into the factory for support.
3. In October 1979, the trademark "Ningyao" was officially registered in the State Administration for Industry and Commerce. In the same year, comprehensive quality management was implemented.
4. In August 1981, "Ningyao" was awarded the title of "Famous Trademark" by the Autonomous Region Administration for Industry and Commerce.
5. In November 1982, the enterprise implemented the "Ningxia Pharmaceutical Standards" (1981 edition) promulgated by the District Health Bureau.
6. In April 1986, the company began to implement the 1985 version of the new pharmacopoeia.
7. On November 25, 1989, the enterprise was recognized as the first-level enterprise of the autonomous region.
1967~1989 Planned economy period1. In May 1990, a tetracycline production line with an annual output of 100 tons was completed.
2. In 1996, the first phase of the 600-ton "four-salt" technological transformation project was completed and put into production.
3. In 1997, the second phase of the 200-ton "four-salt" expansion technological transformation project was completed and put into production.
4. In December 1998, the company's "Ningyao" trademark was recognized as the third "Ningxia Famous Trademark" by the Autonomous Region Administration for Industry and Commerce.
5. In June 1999, the third phase of the 600-ton "four-salt" technical transformation project was completed and put into production, realizing the "triple jump" of tetracycline hydrochloride, the largest in Ningxia, the largest in China, and the largest in the world.
1. On January 22, 2001, Ningxia Pharmaceutical Factory was restructured and officially registered as: Ningxia Qiyuan Pharmaceutical Co., Ltd.
2. On February 28, 2001, Ningxia Qiyuan Pharmaceutical Co., Ltd. merged and reorganized with Ningxia Traditional Chinese Medicine Factory. In the same year, the company invested 100 million yuan to build a 23,000 square meter modern preparation drug production and marketing base in Yinchuan High-tech Development Zone. .
3. On October 29, 2001, the company invested in the establishment of "Ningxia Qiyuan Pharmaceutical Co., Ltd.".
4. On March 25, 2002, the company registered and established "Ningxia Qiyuan Pharmacy Chain Co., Ltd.".
5. In April 2003, the company acquired 1,286 acres of land in Wangyuan Industrial Park and invested 560 million yuan to build a technical transformation project with an annual output of 2000 tons of erythromycin series products, which was completed and put into operation on September 26, 2004.
Qiyuan Pharmaceutical's predecessor was Ningxia Pharmaceutical Factory. The factory was founded in May 1967. Due to the constraints of the planned economic system, the company was basically in a stagnant situation during the two decades before the reform and opening up. Relying on the planned economy "catering" to barely survive, business operations are struggling.
1. In January 2005, the company's registered trademarks of "Qiyuan", "Ningyao" and "Yinyao" were recognized as the 5th "Ningxia Famous Brand" by the Autonomous Region Administration for Industry and Commerce.
2. In May 2005, the company was listed as an honorary unit in the 2004-2005 "National Honest Unit Honor List" by the "National Honest Unit Honor List" activity office of the News Information Center of People's Daily.
3. During 2005-2012, the company invested 150 million yuan to introduce imported metal film equipment to replace the original plate and frame equipment, which solved the problem of zinc in bacteria residues, reduced the amount of bacteria residues produced, and treated waste residues from the source.
4. From 2012 to 2014, the company invested a total of 30 million yuan in two phases, and adopted anaerobic digestion to treat the pesticide residues in a harmless manner, which solved the long-term peculiar smell generated during the drying of pesticide residues or spraying fertilizer.
5. In 2006, the company invested 470 million yuan to build the second phase of 2,800 tons of erythromycin (including self-provided power plants).
6. In January 2006, the company's technology center was identified as a national enterprise technology center by the Ministry of Science and Technology. In June, the company was approved by the Ministry of Personnel to establish a post-doctoral workstation in the enterprise.
7. In December 2006, the company's raw material erythromycin passed the GMP certification of the State Food and Drug Administration.
8. In 2007, the company successively invested 110 million yuan to build the first phase of the 400,000 tons corn starch and glucose project (200,000 tons of starch, 150,000 tons of glucose).
9. On May 31, 2007, Ningxia Qiyuan Pharmaceutical Co., Ltd. was changed to Ningxia Qiyuan Sinopharm Co., Ltd.
10. In May 2008, the company was awarded the title of "Model Worker's Home" by the Autonomous Region Federation of Trade Unions.
11. In July 2008, the Ningxia Hui Autonomous Region’s Leading Group for the Implementation of Trademark Strategy identified the "Qiyuan" brand as the sixth Ningxia famous trademark.
12. In December 2008, "'Qiyuan' Brand Jinlian Qingre Granules" produced by Ningxia Qiyuan Sinopharm Co., Ltd. won the title of "Ningxia Famous Brand".
13. From January 2008 to October 2011, the company built 18 wastewater treatment reactors (volume 36110 cubic meters), 91,000 cubic meters of aerobic aeration tanks, 15,000 cubic meters of secondary sedimentation tanks, and others in three phases. The matching pool is 22,000 cubic meters, which ensures that the company's wastewater discharges up to the standard.
14. In March 2009, Jinlian Qingre Capsules formally obtained the "Certificate of Invention Patent" from the State Intellectual Property Office. This is our company's first product with completely independent intellectual property rights.
From 2005 to 2010, steady development1. In January 2011, the enterprise's 300T azithromycin project commissioned.
2. From 2010 to 2014, the company invested more than 5 million yuan to cover the adjustment tank, hydrolysis acidification tank, anaerobic tank, etc. of the sewage treatment station; invested 800,000 yuan to recycle all the sterilization and exhaust gas of the fermentation workshop .
3. In 2012, the company invested 80 million yuan to build 8 sets of 11,000 cubic meters anaerobic digestion tanks to treat waste slag, and comprehensively use the waste slag; invested 7 million yuan to build a new boiler desulfurization project. After stable trial operation in 2013, Passed the acceptance of the environmental protection department.
4. In January 2013, the company successively invested 136.53 million yuan in the construction of sorbitol project and VC extraction project.
5. In April 2013, Ningxia Qiyuan Pharmacy Chain Co., Ltd. was renamed Ningxia Qiyuan Pharmaceutical Co., Ltd.
6. On October 16, 2014, the company registered and established Ningxia Yuyuan Biotechnology Co., Ltd.
7. In November 2014, the company's clarithromycin project was commissioned.
8. In 2014, the company invested 18 million yuan to complete the boiler smoke and dust upgrading transformation project, adopting electric dust removal + water film dust removal technology for advanced flue gas treatment to ensure that the flue gas emission standards after the upgrade; investment 17.6 million yuan, completed The boiler flue gas denitrification project ensures that the enterprise's nitrogen oxide emissions meet the standards.
9. In 2014, the company invested 4 million yuan to build two 11,000 cubic meters of emergency emergency storage tanks (maintenance tanks), which eliminated potential environmental safety hazards caused by the leakage of existing anaerobic tanks.
10. In 2015, the company invested 96 million yuan to adopt nanofiltration membrane + MBR membrane + MVR falling film evaporator technology for advanced sewage treatment and high salt water recovery.
11. In 2017, the company invested 35 million yuan to independently design and complete 9 types of odor control and renovation projects, mainly sealing the tanks and pools of the workshop, and adding odor control equipment and facilities.
After the completion of the first phase of the erythromycin project, the company invested in the second phase of the erythromycin project (including self-provided power plants) and 200,000 tons of starch and 150,000 tons of glucose projects, which gradually expanded the company's production scale. At the same time, environmental protection was strengthened to solve the problem of zinc in bacterial residues and ensure that wastewater discharges up to standards.
